This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Galapagos Past Earnings Performance

Past criteria checks 2/6

Galapagos's earnings have been declining at an average annual rate of -14.1%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 16% per year. Galapagos's return on equity is 0.2%, and it has net margins of 1%.

Key information

-14.1%

Earnings growth rate

-9.1%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate16.0%
Return on equity0.2%
Net Margin1.0%
Next Earnings Update23 Feb 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Galapagos makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XTRA:GXE Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2257762620
30 Jun 22505-812300
31 Mar 22507-1262190
31 Dec 21485-1252020
30 Sep 21474-2011950
30 Jun 21537-2192020
31 Mar 21488-2721960
31 Dec 20478-3111850
30 Sep 20455-3681680
30 Jun 20972751570
31 Mar 209481451200
31 Dec 19835149970
30 Sep 19865280740
30 Jun 19324-66520
31 Mar 19314-41440
31 Dec 18318-29400
30 Sep 18255-743496
30 Jun 18185-1263096
31 Mar 18161-1392896
31 Dec 17156-116270
30 Sep 17193-402668
30 Jun 17176-272668
31 Mar 1717742568
31 Dec 16152542468
30 Sep 1678-492349
30 Jun 1672-522249
31 Mar 1655-682149

Quality Earnings: GXE has a large one-off gain of €14.2M impacting its last 12 months of financial results to 30th September, 2022.

Growing Profit Margin: GXE became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GXE has become profitable over the past 5 years, growing earnings by -14.1% per year.

Accelerating Growth: GXE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: GXE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).


Return on Equity

High ROE: GXE's Return on Equity (0.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/02/01 05:50
End of Day Share Price 2022/11/04 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Galapagos NV is covered by 34 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
René VerhoefABN AMRO Bank N.V.
Emily FieldBarclays
Patrick TrucchioBerenberg